{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T10:22:43Z","timestamp":1780568563252,"version":"3.54.1"},"reference-count":18,"publisher":"Japanese Society of Internal Medicine","issue":"20","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2023,10,15]]},"DOI":"10.2169\/internalmedicine.1094-22","type":"journal-article","created":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T22:10:59Z","timestamp":1677622259000},"page":"3037-3041","source":"Crossref","is-referenced-by-count":7,"title":["Recurrent Guillain-Barr\u00e9 Syndrome Associated with the Second Episode of &lt;i&gt;Campylobacter jejuni&lt;\/i&gt; Infection"],"prefix":"10.2169","volume":"62","author":[{"given":"Kiyoshi","family":"Takemoto","sequence":"first","affiliation":[{"name":"Division of Critical Care Medicine, Nara Prefecture General Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Kawahara","sequence":"additional","affiliation":[{"name":"Department of Neurology, Nara Prefecture General Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Atagi","sequence":"additional","affiliation":[{"name":"Division of Critical Care Medicine, Nara Prefecture General Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Yuki N, Hartung HP. Guillain-Barr\u00e9 syndrome. N Engl J Med 366: 2294-2304, 2012.","DOI":"10.1056\/NEJMra1114525"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Rees JH, Soudain SE, Gregson NA, Hughes RA. <i>Campylobacter jejuni<\/i> infection and Guillain-Barr\u00e9 syndrome. N Engl J Med 333: 1374-1379, 1995.","DOI":"10.1056\/NEJM199511233332102"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Winer JB. Guillain-Barr\u00e9 syndrome. BMJ 337: 227-231, 2008.","DOI":"10.1136\/bmj.a671"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Winer JB. Guillain-Barr\u00e9 syndrome: clinical variants and their pathogenesis. J Neuroimmunol 231: 70-72, 2011.","DOI":"10.1016\/j.jneuroim.2010.09.017"},{"key":"5","unstructured":"5. Das A, Kalita J, Misra UK. Recurrent Guillain-Barr\u00e9 syndrome. Electromyogy Clin Neurophysiol 44: 95-102, 2004."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barre&apos; syndrome. Ann Neurol 27: S21-S24, 1990.","DOI":"10.1002\/ana.410270707"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Kuitwaard K, van Koningsveld R, Ruts L, Jacobs BC, van Doorn PA. Recurrent Guillain-Barr\u00e9 syndrome. J Neurol Neurosurg Psychiatry 80: 56-59, 2009.","DOI":"10.1136\/jnnp.2008.156463"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Ito H, Hatanaka Y, Fukami Y, et al. Anti-ganglioside complex antibody profiles in a recurrent complicated case of GQ1b-seronegative Miller Fisher syndrome and Bickerstaff brainstem encephalitis: a case report. BMC Neurol 18: 72, 2018.","DOI":"10.1186\/s12883-018-1077-5"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Luan H, Zhang P, Zhen M, Li M, Wang X, Xu J. Recurrent Guillain-Barr\u00e9 syndrome presenting as pharyngeal-cervical-brachial variant with three species of ganglioside antibodies: case report. BMC Neurol 22: 441, 2022.","DOI":"10.1186\/s12883-022-02955-0"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Takahashi H, Kimura T, Yuki N, Yoshioka A. An adult case of recurrent Guillain-Barr\u00e9 syndrome with anti-galactocerebroside antibodies. Intern Med 57: 409-412, 2018.","DOI":"10.2169\/internalmedicine.8941-17"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. J Hwang, Kwon YJ, Kim JK, Kim NJ, Baek SH. Recurrent Guillain-Barr\u00e9 syndrome with anti-GT1a and anti-GQ1b ganglioside antibodies. J Clin Neurol 15: 404-406, 2009.","DOI":"10.3988\/jcn.2019.15.3.404"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Pyun SY, Jeong JH, Bae JS. Recurrent Guillain-Barr\u00e9 syndrome presenting stereotypic manifestations, positive antiganglioside antibodies, and raid recovery. Clin Neurol Neruosurg 139: 230-233, 2015.","DOI":"10.1016\/j.clineuro.2015.10.022"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Notturno F, Kokubun N, Sekiguki Y, et al. Demyelinating Guillain-Barr\u00e9 syndrome recurs more frequently than axonal subtypes. J Neurol Sci 365: 132-135, 2015.","DOI":"10.1016\/j.jns.2016.02.053"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Ishii J, Yuki N, Kawamoto M, et al. Recurrent Guillain-Barr\u00e9 syndrome, Miller Fisher syndrome, and Bickerstaff brainstem encephalitis. J Neurol Sci 364: 59-64, 2016.","DOI":"10.1016\/j.jns.2016.03.008"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Yuki N, Taki T, Inagaki F, et al. A bacterium lipopolysaccharide that elicits Guillain-Barr\u00e9 syndrome has a GM1 ganglioside-like structure. J Exp Med 178: 1771-1775, 1993.","DOI":"10.1084\/jem.178.5.1771"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Tatsumoto M, Koga M, Gilbert M, et al. Spectrum of neurological diseases associated with antibodies to minor gangliosides GM1b and GalNAc-GD1a. J Neuroimmunol 177: 201-208, 2006.","DOI":"10.1016\/j.jneuroim.2006.04.005"},{"key":"17","doi-asserted-by":"publisher","unstructured":"17. Kusunoki S, Iwamori M, Chiba A, Hitoshi S, Arita M, Kanazawa I. GM1b is a new member of antigen for serum antibody in Guillain-Barr\u00e9 syndrome. Neurology 47: 237-242, 1996.","DOI":"10.1212\/WNL.47.1.237"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Togawa J, Nakaoku Y, Hagiwara M, et al. Similarities of serum anti-ganglioside antibodies in first and third episodes of recurrent Guillain-Barr\u00e9 syndrome: case report. J Neurol 262: 1360-1362, 2015.","DOI":"10.1007\/s00415-015-7714-7"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/20\/62_1094-22\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T03:24:33Z","timestamp":1697858673000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/20\/62_1094-22\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,15]]},"references-count":18,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.1094-22","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,15]]},"article-number":"1094-22"}}